SynthesisInternational wound journal2026
The Effect of Photobiomodulation in the Management of Leg Ulcers in Sickle Cell Disease: A Systematic Review.
Synthesis in International wound journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leg ulcer (LU) is a chronic complication of sickle cell disease (SCD), characterised by intense pain, treatment resistance and a high impact on the patient's quality of life (QoL), representing a significant public health challenge. Clinical management involves multifaceted approaches; however, the variability in response to conventional treatments highlights the need for more effective and evidence-based alternatives. Photobiomodulation (PBM) emerges as a promising intervention, with the potential to accelerate tissue healing and reduce pain in patients with SCD-associated LUs. This study conducted a systematic literature review following PRISMA 2020 guidelines, covering relevant databases. Four studies meeting the inclusion criteria were selected, and methodological quality was assessed using the Joanna Briggs Institute tool. Findings indicated that PBM promoted cell growth, accelerated healing and relieved pain, with three studies reporting pain reduction and one study describing a decrease in edema and inflammation. Granulation tissue formation was observed in three of the four studies analysed, and ulcer area reduction was noted in three studies, with one reporting complete healing. Despite the encouraging results, the scarcity of specific studies and the absence of robust randomised clinical trials underscore the need for further research to validate its effectiveness and establish consistent clinical protocols. Expanding these investigations may consolidate PBM as a safe, effective and cost-efficient therapeutic option for patients with SCD-related LUs, contributing to the optimisation of healthcare practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.